Hims has pivoted from selling its knock-of compounded GLP-1s to an official partnership with Novo Nordisk to sell branded Wegovy and Ozempic. They are slowly becoming an All in 1, diversified telehealth company, acting like the Amazon for pharmaceuticals. With Q1 2026 Earnings around the corner, is alexander volkov this enough to break through the $30 range and return to All time Highs?
In this video, I'm deep diving into what Hims & Hers do, I'll be looking at the recent Novo Nordisk law suit and partnerships, the strong and fast growth, the growing subscription base, the margins and the overall financials behind the company . I will also be sharing if I think this growth company is a buy at these prices?
What are your thoughts on the controversy around HIMS? Are you buying this dip or waiting for the Earnings on the 11th of May? Let me know in the comments!
(I've also included the web app I used in the description below for reference)
0:00 Intro
0:28 Background into Hims & Hers
1:44 The Unique Business Model
2:41 The Services They Offer
4:03 Financial Side happy mothers day images of the Business
6:05 Recent News and Events affecting Hims
9:07 Future Growth Strategy
9:46 Potential Risks
10:17 The Bull VS zara larsson Bear Case
11:19 The competitors to Hims
#hims #himsandhers #telehealth #novonordisk #dtc #healthcare #investing #ozempic #peptides #wegovy #hairloss
